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ABSTRACT
Objective: To determine the economic impact of child-
hood varicella vaccination in France and Germany.
Methods: A common methodology based on the use of a
varicella transmission model was used for the two coun-
tries. Cost data (2002€) were derived from two previous
studies. The analysis focused on a routine vaccination
program for which three different coverage rates (CRs)
were considered (90%, 70%, and 45%). Catch-up strat-
egies were also analyzed. A societal perspective including
both direct and indirect costs and a third-party payer per-
spective were considered (Social Security in France and
Sickness Funds in Germany).
Results: A routine vaccination program has a clear posi-
tive impact on varicella-related morbidity in both coun-
tries. With a 90% CR, the number of varicella-related
deaths was reduced by 87% in Germany and by 84% in
France. In addition, with a CR of 90%, routine varicella
vaccination induces savings in both countries from both
societal (Germany 61%, France 60%) and third-party
payer perspectives (Germany 51%, France 6.7%). For
lower CRs, routine vaccination remains cost saving from
a third-party payer perspective in Germany but not in
France, where it is nevertheless cost-effective (cost per life-
year gained of 6521€ in the base case with a 45% CR).
Conclusion: Considering the impact of vaccination on
varicella morbidity and costs, a routine varicella vaccina-
tion program appears to be cost saving in Germany and
France from both a societal and a third-party payer
perspective. For France, routine varicella vaccination
remains cost-effective in worst cases when a third-party
payer perspective is adopted. Catch-up programs provide
additional savings.
Keywords: children vaccination, economic evaluation,
model, varicella.
Introduction
The varicella vaccine, initially developed in Japan
[1], is a live attenuated virus vaccine speciﬁc for
varicella zoster virus (VZV), the virus responsible
for varicella and zoster. Following Japan, where the
use of the OKA/Biken strain of the varicella virus
started in 1974, the United States licensed in 1995
the OKA/Merck strain of the varicella vaccine.
Since that time, a growing proportion of young
Americans (76.3% of children aged 19–35 months
in 2001 [2]) have been vaccinated against varicella.
In many European countries, the debate over tar-
geted vaccination versus mass vaccination remains
open. In this context, the question of the value of
varicella vaccination has been addressed in several
economic evaluations focused on European [3–7]
and other developed countries [8–13] over the last
decade. These evaluations can be divided in two cat-
egories: those putting forward the beneﬁts associ-
ated with a routine vaccination [3,4,6,9–14] and
those pointing out the potential risks associated to
mass childhood vaccination [5–8].
The advantages of a routine vaccination program
derives from the possibility of obtaining through
vaccination a dramatic reduction of the burden
associated with varicella in terms of morbidity
(complications and deaths) and socioeconomic
consequences (treatment costs, productivity losses,
absenteeism from school). Considering that vari-
cella affects all individuals in absence of vaccina-
tion, this burden should not be underestimated. The
potential risks of varicella vaccination include the
increase in the proportion of adult cases that are at
high risk of severe disease and the impact on zoster
incidence [15].
Analyzing the value of varicella vaccination
requires a thorough examination of both epidemi-
ological and socioeconomic impact of the vaccina-
tion strategies under consideration. Although not
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considered in most of the oldest studies [4,7,9–
11,13], explicit use of a dynamic transmission
model is becoming a standard method for economic
evaluations that focus on varicella vaccination
[3,5,6,8,12].
All economic evaluations performed thus far,
however, remain focused on one country. We pro-
pose here a joint analysis of the epidemiological and
economic impact of universal varicella vaccination
in France and Germany. The advantages of this
approach derive from the extensive comparisons
that can be made between countries regarding data
and results.
Methods
Epidemiological Impact of  Vaccination
Model. The assessment of the epidemiological
impact of vaccination in France and Germany was
conducted with the same disease transmission
model.
Varicella vaccination raises questions about the
shift in the age distribution of the disease and on the
efﬁcacy of the vaccine. These elements are captured
by the age-structured model initially developed by
Halloran et al. for the United States [16]. Following
other economic evaluations [3,5,6,8,12], we used
this dynamic model for analyzing varicella trans-
mission. It enables us to simulate the impact of vac-
cination for an entire population, divided here in
100 birth cohorts of identical size, on the number
and age distribution of varicella cases. A graphical
representation of the state variables characterizing
the possible status of individuals regarding varicella
is presented in Figure 1.
Given its dynamic nature, this model is able to
assess direct, as well as indirect effects, of vaccina-
tion [17], i.e., herd immunity effects. This kind of
phenomenon  is  due  to  the  reduction  of  the  risk
to contract an infectious disease as a result of the
decrease in the number of individuals susceptible to
transmit it.
The main speciﬁcity of this model relies on the
detailed representation of the protection acquired
through vaccination. Three vaccination status are
considered: 1) protection against the disease; 2) par-
tial protection with a risk to develop an attenuated
version of the disease called breakthrough varicella;
and 3) primary failure with an unchanged risk to
contract varicella. These three status correspond,
respectively, to the transition from S(a,t) to, respec-
tively, V(a,t), Sv(a,t), and S(a,t) state variables.
Waning immunity and boosting phenomena affect-
ing individuals protected by the vaccine are also
taken into account.
Epidemiological data. Inputs required for the
model can be divided in two categories: generic
data that can be used for all countries and coun-
try-speciﬁc data. Generic data are presented in
Table 1.
If no differences between countries are expected
in reference to varicella duration, one can argue that
some differences exist regarding fatality rates. The
main difﬁculty is obtaining accurate data: because
deaths due to varicella complications are a rare
event, ofﬁcial statistics are often affected by under-
reporting. In addition, these statistics do not give
any direct information on the age-speciﬁc fatality
rates that are important to consider, given the pos-
sible age shift induced by vaccination. Nevertheless,
it is unlikely to have big differences among devel-
oped countries regarding fatality rates. Then, we
used for each country age-speciﬁc varicella fatality
rates obtained through a meta-analysis of US and
Figure 1 Graphical representation of  the
model’s state variables. a = age; t = time;
b = relative residual susceptibility of  a vacci-
nated susceptible; f(a,t) = proportion of
those vaccinated acquiring complete protec-
tion against disease; g(a,t) = proportion of
remaining at least partially susceptible;
k = boosting effect; Greek symbols represent
the various transition probabilities.
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UK data [18,19]. For similar reasons, we used,
for both countries, age-speciﬁc complication rates
provided by a French varicella sentinel surveillance
network [20].
In reference to vaccine efﬁcacy parameters, we
used Brisson et al. data [21] from the results of clin-
ical trials to assess the efﬁcacy of the OKA/Merck
varicella vaccine (VARIVAX®, Merck & Co., Inc.,
Westpoint, PA), rather than those initially used by
Halloran et al. [16], which were based on experts’
opinions. For the best and worst cases, we used val-
ues derived from the conﬁdence interval associated
to the breakthrough rate in the clinical trial consid-
ered by Brisson et al. for their base-case results
(4.1–8.1% over a 7-year follow-up period) [22].
These values are in fact adapted to the observations
made since the introduction of the varicella vaccine
in the United States [23–25].
Following Lieu et al. [12] and Brisson et al. [21],
we considered breakthrough varicella in vaccinated
as less severe than natural varicella and therefore
associated with a lower risk of complications and
death.
Data that are country-speciﬁc refer primarily to
the demographic characteristics of the population.
We used national statistics for both age-speciﬁc
mortality rates in the general population and size of
cohorts at birth: 735,000 in Germany (Statistisches
Bundesamt 2001) and 775,000 in France (INSEE
2001). The other important country-speciﬁc ele-
ment is the propensity of the VZV virus to circulate
into a given population. This propensity is closely
related to social and geographic characteristics of
the country (e.g., density of the population, age at
which children are sent to school). The transmission
rates across and within age groups gathered in a
“Who Acquires Infection From Whom” (WAIFW)
matrix are the key element of an age-structured
infectious disease dynamic model [17]. These trans-
mission rates can be calculated with the help of
seroprevalence data or case notiﬁcations [26]. The
same 7 ¥ 7 WAIFW matrix is used for both coun-
tries. The age classes considered are: <1, 1–2, 3–4,
5–9, 10–14, 15–19, >20 years. This matrix is struc-
tured to take into account the key role of contacts
among children of school age (5–9 years) in vari-
cella transmission. Considering the importance of
this element on the impact of varicella vaccination,
we tried to obtain a good ﬁt of observed data. We
used seroprevalence data for Germany [27] and
varicella cases reported by the sentinel network for
France [20].
Table 1 Epidemiological data
Variable Base case Range
Varicella characteristics [16]
Duration of  the latent period 14 days
Duration of  the infectious period 7 days
Mean duration of  protection through maternal antibodies 180 days
Vaccine efﬁcacy [21,22]
Proportion of  individuals for whom vaccination leads to a seroconversion 99%  99–99
Proportion of  individuals having seroconverted and protected by vaccination 97%  97–97
Relative propensity of  partly susceptible vaccinees to contract the virus 73%  50–73
Relative infectiousness of  vaccinees developing breakthrough varicella 50%  20–100
Proportion of  protected vaccinated subjects immunized after re-exposure to the virus 91%  91–100
Rate at which protected vaccinees become partly susceptible to develop varicella 3.1% 2.1–5.0
Age-speciﬁc fatality rates [18,19]
<1 year 4.8 ¥ 10-5 1.5–8.2
1–4 years 0.7 ¥ 10-5 0.3–1.2
5–9 years 0.8 ¥ 10-5 0.4–1.3
10–14 years 1.1 ¥ 10-5 0.1–2.1
15–19 years 5.5 ¥ 10-5  1–10.0
20–44 years 3.3 ¥ 10-5 2.5–4.3
45–64 years 11.8 ¥ 10-5 6.8–18.0
≥65 years 78.6 ¥ 10-5 57.2–99.8
Age-speciﬁc complication rates [20]
<1 year 6.29% 3.4–9.4
1–4 years 4.74% 3.9–5.6
5–9 years 3.45% 2.5–4.5
10–14 years 3.52% 0.7–6.7
15–19 years 2.37%  0–7.1
≥20 years 8.81% 5.2–12.7
Relative propensity* of  breakthrough varicella to induce medical care or death [12,21]
Complications 1%  0–5
Death 1%  0–1
*Compared with natural varicella.
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The value of force of infection by age category is
presented in Figure 2. The trend is similar for both
countries, with a sharp decrease of force of infection
for the oldest age groups and some differences exist-
ing for the youngest ones.
Following Halloran et al. [16] and Brisson et al.
[21], we also considered, in addition to the
main role of native varicella cases, the role of
zoster cases and immigration of infectives from an
external reservoir in VZV transmission by adding
for each country 0.001 to the force of infection (l
(a,t)).
Age distribution of varicella vaccination was
considered to be similar in each country to the
one observed for measles–mumps–rubella (MMR)
vaccination (i.e., 25.3% between 12 and 15
months, 63.2% between 15 and 24 months, 11.5%
between 2 and 3 years in Germany [28]; 11.1%
between 6 and 12 months, 82.2% between 1 and
2 years, 6.7% between 2 and 6 years in France
[29]).
Economic Analysis
Vaccination strategies and scenarios. The economic
analysis is based on the comparison of epidemiolog-
ical and economic consequences of a routine vacci-
nation strategy (routine vaccination program +
medical treatment of residual varicella cases) with
those of a “no vaccination” strategy (medical treat-
ment of varicella cases). The economic impact of
varicella vaccination was mainly assessed through a
comparison of the costs associated with these two
strategies. When vaccination was not cost-saving,
we calculated the incremental cost per life-year
gained of varicella vaccination above no vaccina-
tion. Life-years lost were calculated by using case-
fatality rates associated with varicella and life
expectancy at each age in the general population.
Three scenarios were considered for coverage
rate: a high scenario (vaccination of 90% of
children having not contracted varicella at the age
of vaccination), a medium scenario (70%), and a
low scenario (45%). The target vaccination
coverage was supposed to be reached in 5 years in
both countries (i.e., 40%, 65%, 85%, 95%,
100%).
Efforts are ongoing to develop an effective com-
bination of varicella and MMR vaccines [30]. We
considered here a vaccination strategy for which a
joint administration of varicella and MMR vaccine
was promoted. This is why we considered, ﬁrst, that
ﬁrst, the age distribution of varicella vaccination
matches the one observed for MMR and, second,
that the joint administration of these two vaccines is
frequent.
In addition to the main analysis that focused on
routine varicella vaccination, the value of catch-up
programs was studied. We report here the analysis
for a massive catch-up of 2 to 11 years carried out
at the ﬁrst year of routine vaccination even if we
considered also strategies that focused on a speciﬁc
age group, i.e., 6-year-old or 11-year-old children.
We assumed that, with the catch-up program, 90%
of susceptible and immune children were vacci-
nated. To reach this target, we took into account the
fact that some useless vaccination were performed,
so we increased the vaccination cost by 15% within
the catch-up program, according to Lieu et al. [12],
and in order to keep computations as simple as
possible.
Following Lieu et al. [12] and almost all other
economic evaluations on varicella vaccination, we
did not take into account the impact of varicella
vaccination on zoster in the analysis.
Figure 2 Force of  infection according to age in Germany and
France.
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Perspectives  and  time  frame. Two different per-
spectives were  considered  for  the  assessment  of
the value of vaccination programs: 1) a societal per-
spective including all types of costs (direct and indi-
rect); and 2) a third-party payer perspective limited
to costs directly supported by health-care schemes
(Social Security in France, Sickness Funds in Ger-
many). The latter includes 1) all in Germany or a
part of the varicella treatment costs in France; 2) the
intervention costs; and 3) the sick leaves paid to sick
adults in France and to parents of ill children in
Germany.
In the base case, varicella consequences were
assessed over a 50-year range. Time frames of 25
and 100 years were also considered in the sensitivity
analysis. Both costs and outcomes were discounted
at a 3% rate (range 0–5% in sensitivity analyses) in
calculations of cost per life-year gained.
Varicella treatment costs. Varicella treatment costs
included consultations, medications, hospitaliza-
tions, and additional examinations. The use of med-
ical resources was based on two speciﬁc surveys
among general practitioners and pediatricians: a
retrospective survey carried out in 2000 in Germany
in which 1334 varicella cases were reported [3] and
a prospective survey carried out from 1994 to 1995
in France that included 1832 varicella patients [6].
Updated unit costs of resources were used to
express results in 2002€. All these elements led to
the use of medical resources and varicella treatment
costs presented, respectively, Table 2 and Figure 3.
Banz et al. [3] reported consultations, visits, and
advice calls in varicella cases. Nevertheless, the Ger-
man law on infectious diseases requires notably at
least two medical consultations for children when a
physician is contacted (90% of the cases). Follow-
ing expert opinions, we therefore modiﬁed the data
from Banz et al. to take this element into account.
This resulted in a larger number of physician con-
tacts for children 0 to 12 years old (1.8 vs. 1.75) but
in a smaller number for adults and teenagers (1.8 vs.
2.2).
We considered that, in 80% of children cases in
France, consultations were performed by general
practitioners; other cases were treated by pediatri-
cians. These data were issued from a French panel
data (Dorema) about medical care consumption . In
Germany, according to expert opinion, this propor-
tion was only 10% in children less than 12 years,
but 75% in adolescents (<18 years).
With respect to consultation costs, we used
national tariffs for France (Nomenclature Générale
des Actes Professionnels) completed by average
extra fees asked from their patients by physicians.
This led to 24.9€ for general practitioners and 26.4€
for pediatricians. We also used national tariffs in the
German case (Einheitlicher Bewertungsmaßstab)
with an average point value of 0.0375€, compared
with 0.036€ in Banz et al. This resulted in much
Table 2 Varicella treatment and work loss costs in different age classes (2002€)
Variable Germany France
Mean number of  medical consultations per varicella case* [3,6]
0–17 years 1.8 (1.6–2.0) 1.19 (1.16–1.23)
≥18 years 1.8 (1.6–2.0) 1.55 (1.46–1.73)
Cost of  pharmaceutical prescriptions per varicella case† [3,6]
0–12 years 11.2€ (9.9–12.4) 13.0€ (12.5–13.6)
13–17 years 11.9€ (10.6–13.2) 13.0€ (12.5–13.6)
≥18 years 11.9€ (10.6–13.2) 26.3€ (22.0–31.1)
% of  cases in which additional examinations are performed [6]
0–17 years 0% (0–0) 0.8% (0.36–1.33)
≥18 years 0% (0–0) 6.4% (2.4–11.2)
% of  varicella cases requiring hospitalizations [3,6]
0–12 years 0.67% (0.67–0.67) 0.36% (0.12–0.66)
13–17 years 1.55% (1.55–1.55) 0.36% (0.12–0.66)
≥18 years 1.55% (1.55–1.55) 1.95% (0.0–4.5)
Cost of  a hospital stay due to varicella
0–12 years 3032€ 1187€
13–17 years 2181€ 1187€
≥18 years 2181€ 2087€
Mean number of  workdays lost per varicella case [3,6]
0–17 years 0.7 (0.6–0.8) 0.6 (0.5–0.7)
≥18 years 5.3 (4.2–6.4) 5.7 (4.2–7.6)
*Mean number of  medical contacts reported by Banz et al. (1.75 for 0–12 years old, 2.2 for >12 years old), adapted to be in accordance with German law regarding
infectious disease.
†1995 French data updated using a price index for refundable drugs (-2%, Ecosanté Database), 1999 German data updated using a General Price index (+4%, Eurostat
data).
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lower ﬁgures than in the French case: 9.9€ for
general practitioners and 10.7€ for pediatricians.
German physicians, however, also received fees for
additional counseling services for an average
amount of 7.6€ [3].
Costs associated with hospitals stay derived from
national DRG systems for France (1187€ for chil-
dren, 2084€ for adults). In Germany, Banz et al.
data updated with the help of national statistics
(Statistiches Bundesamt) were considered (3032€
for children, 2181€ for adults).
Costs associated with additional examinations
were only considered in France (data from a previ-
ous publication updated to 2002€). Over-the-
counter drugs were not included.
Considering the lower degree of severity of break-
through varicella [31,32], we assumed for both
countries that breakthrough cases required less med-
ical care than natural varicella cases. Following Lieu
et al. [12] and Brisson et al. [21], we assumed that
hospitalization rate was 1% (range 0–5) of the one
associated with natural varicella. For other elements
of medical care, we assumed that breakthrough vari-
cella involved 50% (range 30–70) of the use of med-
ical resources considered for natural varicella cases.
This is a more conservative assumption than the one
adopted by Getsios et al. [9] in the Canadian case
(20%), but these authors assumed that the relative
risk of hospitalization was 10% and not 1%.
Vaccination costs. Data on the price of the vaccine
were provided by Sanoﬁ Pasteur MSD, the vaccine’s
manufacturer.  They  took  into  account  the differ-
ent sectors––private and public––in which the vac-
cine is likely to be purchased (France 45.50€ ± 10%
and Germany 50.00€ ± 10%). Following previous
publications [6,12], we assumed that
approximately  1.5%  of  vaccinations  (range 1–2)
lead to an additional medical consultation because
of side effects.
We assumed for the routine vaccination program
that, in 55% (range 45–70) of the cases in France
and in 70% (range 60–80) of the cases in Germany,
varicella vaccine would be administered jointly with
the MMR vaccine. When varicella vaccine is jointly
administered with the MMR vaccine, no adminis-
tration costs are incurred. For the catch-up pro-
gram, we considered that varicella vaccination was
always administered separately. Panel data about
medical care consumption, X-ponent data in Ger-
many and Dorema in France, enabled us to deter-
mine the breakdown by type of injector: general
practitioners or pediatricians in the private sector,
and physicians in the public sector.
All these elements resulted in a cost of 56.8€ per
dose administrated (range 51.4–62.1) for the rou-
tine vaccination program in Germany and of 55.8€
(range 47.7–62.9) in France. With respect to catch-
up programs, the vaccination cost was 58.5€ in Ger-
many and 67.7€ in France. These included vaccine
price and costs associated with the administration
of the vaccine and side effects. Material costs (e.g.,
swab) were not taken into consideration.
Indirect costs. Data on the number of workdays
lost due to varicella (Table 2) came in the French
and German case from the same sources as the one
used for treatment costs.
Figure 3 Treatment costs per varicella
case by age (2002€). *The part supported
by Social Security in France is 80% for hos-
pitalization, about 65% for consultations and
examinations, about 50% and 60% for phar-
maceutical prescriptions, respectively, in
children and in adults.
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Productivity losses have been considered in the
societal perspective, and sick leave compensations
have been considered in the payer’s perspective. The
cost of a workday lost was based on Organization
for Economic Cooperation and Development statis-
tics on annual compensation per employee (Ger-
many 150€ and France 165€), with a common basis
of 220 working days per year for both countries.
Productivity costs were computed for workdays lost
due to morbidity alone. With respect to compensa-
tion paid in case of sick leaves, we referred in the
French case to the statistics provided by the main
Social Security system, with an average amount of
23.3€  paid  after  the  third  day  of  sick  leave.  In
the German case, we applied the same calculation
method as that used by Banz et al. based on the
Social Security code: 70% of gross earnings for
employed parents taking care of their sick child.
Indirect costs by varicella case represent in France
97.0€ for the <17-year-olds and 933.4€ for the ≥18-
year-olds. The French Social Security considers sick
leaves for adults participating in the workforce
(average amount 23.3€ paid after the third day of
sick leave). Therefore, in our calculation, the Social
Security supports an average of 90.5€ per adult
case. In Germany, indirect costs equal 105€ and
795€, respectively, for the age group 1 to 12 years,
and for those more than 12 years old. To assess
indirect costs supported by sickness funds, we
applied the same calculation method as that used by
Banz et al. based on the Social Security code (70%
of gross earnings for employed parents taking care
of their sick child, or 73.5€ for children cases).
Sensitivity Analysis
We performed sensitivity analyses of both univari-
ate and multivariate type. The time frame consid-
ered for assessing the consequences of vaccination,
as well as the discount, were subject to univariate
sensitivity analyses. The discount rates considered
in best and worst cases are, respectively, 0% and
5%. We also considered separately the impact of
parameters related to vaccine efﬁcacy, on one hand,
and that of parameters related to cost and varicella-
associated mortality, thereafter called cost parame-
ters, on the other hand. Finally, we also considered
a sensitivity analysis in which the variation of all
parameters except the discount rate is considered.
Results
Epidemiological Results
As shown in Figure 4, a routine vaccination pro-
gram will lead to a sharp drop in the number of nat-
ural varicella cases if a high coverage is achieved. It
should lead also to the appearance of breakthrough
varicella cases among vaccinated individuals. Given
that these breakthrough cases are less severe
[31,32], a routine varicella vaccination program
should result in an overall reduction in varicella-
related deaths and complications for each country
and coverage rate considered (Table 3).
The catch-up program allows further reductions
in morbidity when compared with a routine vacci-
nation program (See Table 4). For example, in the
German case, an additional reduction of 59% in the
number of complications is observed.
Three elements play a key role in the overall
impact of varicella vaccination and explain the
differences between the French and the German
case: vaccine efﬁcacy, age distribution of varicella
vaccination, and VZV propagation in a given
population.
Because we tried to refer to the best available
data, values used in this analysis for vaccine efﬁcacy
differ from the ones used in a previous publication
that focused on the French case. The latter used
Halloran et al.’s [16] value, which resulted in a
much lower number of breakthrough varicella
cases.
The age at which vaccination is performed is also
an important concern with respect to the impact of
a vaccination program [33]. Considering available
data on MMR vaccination, the mean age for vacci-
nation was assumed in this analysis to be about
19 months in both countries. This explains some
of the differences with Banz et al., who consider a
strategy in which all vaccinations are performed
between 1 and 1.5 years of age.
Differences regarding the impact of varicella vac-
cination rely, however, mainly on the way VZV cir-
culates in the country and on related herd immunity
effects. As can be seen in Figure 2, the fraction of
adolescents and adults aged more than 10 years in
varicella cases is more important in France (9%)
than in Germany (5%). Consequently, vaccination
reduces less heavily VZV circulation in France,
especially among adults: -68% of varicella cases
among adults more than 20 years old over the ﬁrst
50 years of vaccination, compared with 79.5% in
the German case.
Economic Results
For France, a total cost per varicella case equals
144.5€ for the group of less than 18-year-olds and
1043.4€ for the group of more than 18-year-olds.
For Germany, it equals 162.5€ for the group of less
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than 12-year-olds and 865.3€ for the group of more
than 12-year-olds.
Annual cost of varicella in France equals to 148€
million from a societal perspective, and 30€ million
from a third-party payer perspective. In Germany it
equals, respectively, to 144€ million and 93€ million.
A routine varicella vaccination program should
result in a substantial decrease in total costs associ-
ated with varicella in both countries: the reduction
over the ﬁrst 50 years is of 61.4% for Germany and
of 59.6% for France for a high coverage rate (see
Fig. 5). This result is mainly due to indirect costs. In
absence of vaccination, productivity losses account
for more than 70% of total costs associated with
varicella (Germany 70.5%, France 74%). Because a
vaccination program enables to reduce heavily the
number of workdays lost due to varicella, this pro-
gram is highly proﬁtable from a societal perspective
(mean annual number of workdays lost prevented
with a high coverage rate: about 590,000 in Ger-
many and 540,000 in France).
If one considers only costs supported by social
security schemes, differences among countries are
more important: a routine vaccination program
results in a decrease of 51.1% of costs in Germany
compared with 6.7% in France. This difference can
again be explained by sick leave compensations.
German parents who stop working for a few days
in order to take care of their sick child can receive
compensation. This makes a routine vaccination
program highly proﬁtable from a third-party payer
perspective in the German case. Compensations are
also paid in the French case but essentially to adults
having a sick leave due to varicella. When sick leave
compensations are not considered, results are still
cost-saving in Germany, but there is a slight
Figure 4 Evolution of the annual number
of  natural and breakthrough varicella cases
after the implementation of  a routine vacci-
nation program in Germany and France
(coverage rate 90%—base case).
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Table 3 Average annual number of  cases, hospitalizations, deaths, and life-year lost associated with varicella before and after vac-
cination over a 50-year period
a. FRANCE*
No vaccination Routine vaccination
of  toddlers
Routine vaccination and
catch-up the ﬁrst year
High coverage rate (90%)
Natural varicella cases 767,221 49,879 23,147
Breakthrough varicella  0 21,203 21,918
Complications 35,506 2,720 1,401
Deaths  11  2  1
Years of  life lost  673  70.5  41.8
Medium coverage rate (70%)
Natural varicella cases 767,221 197,627 162,893
Breakthrough varicella  0 50,960 58,016
Complications 35,506 10,317 8,446
Deaths  11  6  5
Years of  life lost  673  250  209
Low coverage rate (45%)
Natural varicella cases 767,221 429,254 389,767
Breakthrough varicella  0 43,277 54,193
Complications 35,506 20,484 18,495
Deaths  11  8  8
Years of  life lost  673  438  398
b. GERMANY*
No vaccination Routine vaccination
of  toddlers
Routine vaccination and
catch-up the ﬁrst year
High coverage rate (90%)
Natural varicella cases 725,550 48,758 18,368
Breakthrough varicella  0 9,541 11,604
Complications 32,520 2,280  937
Deaths  10  1  1
Years of  life lost  529  47  24
Medium coverage rate (70%)
Natural varicella cases 725,550 175,823 142,382
Breakthrough varicella  0 37,954 43,269
Complications 32,520 8,096 6,544
Deaths  10  7  6
Years of  life lost  529  165  138
Low coverage rate (45%)
Natural varicella cases 725,550 398,919 362,269
Breakthrough varicella  0 37,120 45,513
Complications 32,520 17,840 16,129
Deaths  10  7  6
Years of  life lost  529  326  296
*Birth cohort size = 774,800 in France (INSEE 2001) and 734,478 in Germany (Statistisches Bundesamt 2001).
Table 4 Sensitivity analysis on annual savings (2002 millions of  euros) from a societal and a third-party payer perspective asso-
ciated to a routine varicella vaccination program in Germany and France (high coverage rate (90%))
Germany France
Base
case
Lower
bound
Upper
bound
Base
case
Lower
bound
Upper
bound
Societal perspective 87.9 88.8
All parameters 34.7 111.4 14.1 119.7
Cost parameters 61.3 114.7 65.9 111.3
Discount rate 84.9 91.2 89.6 85.1
Number of  years for the assessment of  varicella consequences 84.8 84.6 94.1 70.6
Vaccine efﬁcacy parameters 75.0 90.0 75.0 90.0
Health system perspective 47.5 2.0
All parameters 25.9 96.6 -12.5 10.4
Cost parameters 29.7 65.3 -5.4 8.9
Discount rate 45.2 50.5 2.2 1.3
Number of  years for the assessment of  varicella consequences 44.3 48.4 3.0 -0.7
Vaccine efﬁcacy parameters 43.9 48.1 -5.2 3.1
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increase in costs in France from a payer perspective.
Sick leave compensations, however, have to be
included to reﬂect the German and the French
context.
More generally, marked differences exist in direct
medical costs associated with varicella (see Table 2
and Fig. 3). For example, the cost of pharmaceutical
prescriptions for adults is more than twice higher in
France (26.3€) than in Germany (11.9€.)
Achieving a 90% coverage rate prevents in the
French case the slight increase of costs supported by
the Social Security system observed for lower cov-
erage rates (+1.3% for a 70% coverage rate and
+5.3% for a 45% coverage rate). It has to be noted
that even if varicella vaccination is not cost-saving
at a low coverage rate; it remains cost-effective with
a cost per life-year gained of 6521€ [34].
The results associated with the catch-up program
are in line with those observed for routine vaccina-
tion. Massive catch-up strategy during the ﬁrst year
of vaccine marketing leads to a decrease of 59%
and 49% in complications in Germany and France,
respectively. Similar ﬁgures for deaths range from
38% to 31%. From an economical point of view,
catch-up brings additional savings compared with
routine vaccination program alone (+11% in Ger-
many and +8% in France). From a health system
perspective, a catch-up is beneﬁcial in Germany but
brings additional costs in France (respectively 5%
and -5%).
Sensitivity Analyses
Whatever the country and the perspective consid-
ered, the results are essentially sensitive to cost
parameters (see Table 4). This sensitivity does not
call into question savings associated with a routine
varicella vaccination program from the societal per-
spective: with the less favorable assumptions for the
cost parameters (higher vaccine price, lower cost of
varicella episodes), these savings are of 20% in the
German case and of 26% in the French case.
We performed also a best- and a worst-case anal-
ysis where all the variables varied simultaneously.
Economical outcomes vary considerably between
these two extreme situations. This is mainly due to
the fact that we conducted a deterministic sensitiv-
ity analysis instead of a probabilistic one. Indeed,
this latter approach is usually preferred when dif-
ferent parameters vary at the same time, but it was
impossible here because of computer constraints.
In the worst-case analysis, results remain cost-
saving in both countries from the societal perspec-
Figure 5 Average annual costs related to varicella (millions of  2002€) according to the strategy and the perspective considered in France and in
Germany.
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tive. In France, there is an increase in the costs from
the third-party payer perspective (+10€ million vs.
-2 million in the base case). Even in this situation,
varicella vaccination remains cost-effective, with a
cost per life-year gained of 36,342€, which is below
the ratio of 55,100€ per life-year gained found by
Hanslik for the vaccination in seronegative adoles-
cents in France [35].
Discussion
The results of this analysis showed the beneﬁts that
could be gained from a routine varicella vaccination
program in Germany and France. For all coverage
rates considered, this vaccination program has a
positive impact on complications and deaths related
to varicella. With respect to economic aspects, vari-
cella vaccination is cost saving at all coverage rates
for both a societal and a third-party payer perspec-
tive in the German case. In the French case, this
strategy is cost-saving from a societal perspective
and also from a third-party payer perspective in the
base case as soon as the vaccination coverage is high
enough.
This analysis conﬁrmed a well-known result:
achieving a high coverage rate (within 5 years) is a
key element of the level of beneﬁt gained from
vaccination. Because of herd immunity effects, the
decrease in costs and morbidity associated to vari-
cella is always stronger as the coverage rate rises.
The analysis showed also the additional savings
that can be derived from a catch-up program, espe-
cially in terms of additional morbidity reductions.
These results are globally in accordance with
those reported in previous publications. A study
focused on the French case [6] found that a routine
vaccination was cost-saving at all coverage rates for
both the societal and third-party payer perspective.
The lower vaccination costs used (15€) compared
with ours (55.8€) explain the fact that the results
were even more favorable than ours.
Two previous publications are available in the
German case. The conclusions of our analysis are
similar to the one obtained by Banz et al. [3]. The
main difference between the two relies on the pre-
diction about varicella eradication. By considering
the values from Halloran et al. [16] for vaccine efﬁ-
cacy and by taking not into account the role of
external reservoirs on varicella transmission, Banz
et al predict that varicella could be eliminated in less
than 30 years. We, however, do not predict varicella
elimination here. In an older publication, not based
on a dynamic model, Beutels et al. [4] concluded
that varicella is cost-saving from a societal perspec-
tive but could increase direct medical costs associ-
ated with varicella. We also drew this conclusion
but, because we adopted a third-party payer per-
spective, we considered compensations received by
parents who stop working for caring their sick
child.
Beyond the results directly obtained for France
and Germany, the analysis performed gives some
general insights into the value of varicella vaccina-
tion potentially applicable to each country or, at
least, to each developed country.
The ﬁrst point is that, when a societal perspective
including productivity costs is adopted, an eco-
nomic evaluation surely leads to the conclusion that
a routine varicella vaccination program is cost-
saving. This was exactly the conclusion drawn in
the comprehensive review carried out by Thiry et al.
[37]. Considering that varicella cases have a big
impact in terms of productivity losses, indirect costs
therefore outweigh by far the level of vaccination
costs usually considered. In this analysis, the aver-
age indirect cost by varicella case ranges between
139€ and 143.1€ according to the country, com-
pared with 55.8€ to 67.7€ for vaccination costs.
Regarding this point, it has nevertheless to be
recalled that debates about the right valuation
method for productivity costs (human capital
approach vs. friction costs method notably; see for
example, Brouwer et al. [38]) still exist in the health
economists’ community.
The second point differs from the one drawn by
Thiry et al. [37], who stated that a routine varicella
vaccination is unlikely to provide savings from a
health-care payer perspective. Here we reported
savings from the Sickness Fund in Germany and the
Social Security in France. It is important to note that
we conducted the same analysis in Italy [39], and
that we concluded also that a routine varicella vac-
cination in children could induce savings from both
a societal and a third-party payer perspective.
The third general point is that signiﬁcant differ-
ences exist not only for direct medical costs associ-
ated with varicella but also for the epidemiological
consequences of varicella vaccination. The overall
impact of a varicella vaccination program depends
mainly on three elements, of which two are partly
country-speciﬁc: vaccine efﬁcacy, age distribution of
varicella vaccination, and ability of VZV to be con-
tracted and transmitted in a given population.
The last general point refers to additional savings
provided by catch-up programs in terms of reduc-
tions in morbidity and total costs. It has to be men-
tioned that we focused here on a single strategy
based on a massive catch-up during the ﬁrst year.
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Similar results can be obtained for other catch-up
strategies (e.g., 6-year-old or 11-year-old children)
[36].
Uncertainty underlying some important elements
used in this analysis has to be noted.
First, regarding the complexity of direct and indi-
rect protection acquired through vaccination and
the absence of direct information to date on vaccine
efﬁcacy beyond 10 years, it still remains a relative
uncertainty on the impact of varicella vaccination
on the long term. Nevertheless, no sign indicating
perverse effects of a routine varicella vaccination
program have been reported so far in the US case
regarding this point [40]. Moreover, Krause et al.
[41] reported recently ﬁgures leading them to point
to a possible endogenous boosting due to a reacti-
vation of the vaccine itself when antibody titers
become low. This could have a positive impact on
long-term immunity.
Considering the low degree of severity of break-
through varicella [31,32], we assumed that these
cases were at lower risk than natural varicella cases
with respect to complications, death, and medical
care. These assumptions are supported by data
derived from the US experience of varicella vacci-
nation [23,42] and follow those made in previous
economic evaluations [5,9,12,21]. Nevertheless, we
do not have direct information,
The main point remaining open to discussion
refers to the relationship between zoster and vari-
cella incidence. Following almost all economic eval-
uations on varicella vaccination [37], we chose not
to take into account the impact of varicella vacci-
nation on zoster. Lieu et al. [12] justiﬁed this
assumption by indicating that, if not totally clear,
the impact of varicella vaccination on zoster is pre-
sumably good. Gershon [43] also gave support to
the positive impact of varicella vaccination on
zoster. Jumaan et al. [42] reported in a preliminary
publication no increase of zoster incidence between
1992 and 2001 in western Washington state despite
a 75% to 80% decrease in varicella incidence due to
vaccination.
On the contrary, Brisson et al. [21] pointed out
the potential negative effects in the short- and mid-
term. These potential negative effects are directly
related to the role of varicella invectives for boost-
ing zoster immunity: an indirect effect of a routine
vaccination program leading to a sharp drop of
varicella incidence could be to induce an increase of
annual zoster incidence, among nonvaccinated,
notably during the ﬁrst years of varicella vaccina-
tion (40 years in the worst case). The impact of vari-
cella vaccination on zoster, however, would become
positive in the long run because of the decrease of
VZV carriers in the population and the lowest
severity of zoster when developed by vaccines.
It has to be noted that this model has some lim-
itations. The major one is the assumption used for
the duration of protection from exposure: 20 years
in the base-case analysis. Additional studies on
which to base the parameter estimates would be
needed to include the effect of varicella vaccination
on zoster incidence.
At least, we did not take into consideration the
possible synergies between varicella vaccination and
MMR vaccination. One can argue that one of the
positive impacts of varicella vaccination could be to
help boost MMR vaccination coverage, which
remains low in France and Germany compared with
coverage rates in other European countries [44].
Assessing precisely this impact, however, remains
very difﬁcult.
Conclusion
When one considers the impact of vaccination on
varicella morbidity and costs, a routine varicella
vaccination program appears to be cost-saving from
both a societal and a third-party payer perspective
in Germany and France. Routine varicella vaccina-
tion in France remains cost-effective from a third-
party payer perspective when less favorable
assumptions are considered. Catch-up programs
provide additional savings.
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